Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188479 | 0.90 | PTGER1 (0.52) | PTGER1KMT2ALRRK2MRGPRX4 | |
| SCHEMBL4879716 | 0.84 | SGMS2 (0.56) | PTGER1KMT2A | |
| SCHEMBL9789583 | 0.83 | PTGER1 (0.61) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL14003835 | 0.81 | PTGER1 (0.53) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL4722050 | 0.80 | PTGER1 (0.64) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL29836110 | 0.80 | PTGER1 (0.64) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL487486 | 0.80 | PTGER1 (0.75) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL5465872 | 0.80 | PTGER1 (0.57) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL31743125 | 0.80 | KMT2A (0.67) | PTGER1KMT2ALRRK2CYP2C9KCNA3 | |
| SCHEMBL5460706 | 0.79 | PTGER1 (0.65) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | PTGER1 1/4885KMT2A 1824/4885LRRK2 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.